Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06999187 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

StatusRecruiting
PhasePhase 1
SponsorDren Bio
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 9 words
    • Site contacts updated at 10 of 10 sites
    v10
  2. Site details revised at 1 of 10 sitesv9
  3. Site details revised at 1 of 10 sitesv8
  4. Site details revised at 2 of 10 sitesv7
  5. Site details revised at 1 of 10 sitesv6
Show 4 earlier versionsHide 4 earlier versions
  1. Site details revised at 1 of 10 sitesv5
  2. Start date changed from estimate of Jun 2025 to Jun 3, 2025
    • Site details revised at 1 of 10 sites
    v4
  3. Study sites: 1 to 10v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 2025 to Jun 2025
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Dren Bio
4 trials monitored
See 1 trial at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
3,078 trials monitored
See 172 trials at risk
and 9 more diseases
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Trial Details
NCT Number NCT06999187
Lead Sponsor Dren Bio
Conditions
(from sponsor)		 Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer +4 more
Related terms Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Endometrial Neoplasms, Ovarian Neoplasms, Squamous Cell Carcinoma of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Uterine Cervical Neoplasms
Enrollment 96 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov